Tenowon Tablet (Tenofovir Disoproxil)

Adult dose

2. Patients with Renal Impairment Drug exposure increased significantly when this drug was administered to patients with moderate to severe renal impairment. Therefore, in patients with a baseline creatinine clearance of <50mL/min, the dosing interval for this drug should be adjusted according to Table 1. These dosing interval adjustment recommendations are based on a model of single-dose pharmacokinetic data from patients with various degrees of renal impairment, including patients with end-stage renal disease requiring hemodialysis, who were not infected with HIV or HBV. Since the safety and efficacy of these dosing interval adjustment recommendations have not been clinically evaluated in patients with moderate or severe renal impairment, renal function and clinical response to treatment should be closely monitored in these patients (see Warning 3). No dosing interval adjustment is necessary for patients with mild renal impairment (creatinine clearance 50-80mL/min), and calculated creatinine clearance and serum phosphorus should be monitored regularly (see Warning 3). Table 1 Dosing Interval Adjustment According to Creatinine Clearance Creatinine clearance (mL/min)a ≥50: every 24 hours 30-49: every 48 hours 10-29: every 72-96 hours Hemodialysis patients: every 7 days or approximately 12 hours after dialysisb a. Calculated using ideal (lean body) weight. b. Administer once weekly, generally assuming 3 hemodialysis sessions of approximately 4 hours each per week. This drug should be administered after dialysis is completed. The pharmacokinetics of tenofovir have not been evaluated in patients with a creatinine clearance below 10mL/min who are not receiving hemodialysis; therefore, no dosing recommendations are available for these patients.

Child dose

Adults and pediatric patients 12 years of age and older (35kg or more): Take 1 tablet once daily (equivalent to 245mg of tenofovir disoproxil) for the treatment of HIV-1 or chronic hepatitis B. It may be taken with or without food. Pediatric patients with chronic hepatitis B weighing less than 35kg: Safety and efficacy have not been established. Pediatric patients with renal impairment: There are no data to support dosage recommendations.

This medication may cause sudden worsening of hepatitis if treatment is discontinued; therefore, regular check-ups at the hospital are necessary for several months after stopping treatment. This medication should not be taken by individuals allergic to this product or its ingredients. Patients with lactose intolerance or certain genetic disorders should not take this medication due to the lactose it contains. This medication should not be taken with other medications containing tenofovir, and the risk of side effects may increase when combined with certain drugs. Patients with impaired kidney function should undergo kidney function tests before taking this medication and should regularly check their kidney condition during treatment. Caution is needed when taking this medication with drugs that can strain the kidneys, and in some cases, the dosing interval of this medication may need to be adjusted. This medication may affect bone health, so patients with low bone density or a risk of fractures should consult their physician before taking it. If persistent or worsening pain occurs in bones or muscles, immediate medical attention should be sought. This product contains sulfites, so individuals allergic to sulfites should exercise caution. During treatment, side effects such as headache, diarrhea, nausea, rash, and fatigue may occur; if symptoms are severe, consult a physician. Women who are pregnant or planning to become pregnant should consult their doctor before taking this medication and should only take it during pregnancy when absolutely necessary. Nursing women are advised to avoid breastfeeding as this medication can be transmitted through breast milk. Children under 12 years of age or weighing less than 35 kg should not use this medication, as safety and efficacy have not been established for this population. Elderly patients over 65 years should be cautious due to the potential for decreased kidney and liver function. In case of overdose, seek immediate medical attention for appropriate treatment, and blood dialysis can remove this medication from the body. This medication should be stored at room temperature, and kept out of reach of children. When combined with other medications, there may be potential drug interactions, so it is essential to inform healthcare providers, especially regarding drugs that affect kidney function.

• Hepatitis aggravation
• hypersensitivity
• acute renal failure
• Fanconi syndrome
• hypophosphatemia
• bone pain
• limb pain
• fractures
• muscle pain
• proximal tubular dysfunction

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and it is safe to store at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medication.

Appearance

Light blue almond-shaped film-coated tablet

Package unit

30 tablets/bottle